OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

Summary by AI BETAClose X

OKYO Pharma announced that its lead candidate, urcosimod, will be presented at the ASCRS Annual Meeting, with efficacy and safety results from a proof-of-concept Phase 2 study in neuropathic corneal pain to be shared. Concurrently, a Scientific Advisory Board meeting will convene with leading ophthalmology experts to review this data and provide strategic guidance for the upcoming clinical program, which includes initiating a 150-patient Phase 2b/3 study in the first half of 2026. Urcosimod has received Fast Track designation from the FDA for neuropathic corneal pain, an area with no currently approved therapies.

Disclaimer*

UK 100

Latest directors dealings